BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases | Zendy

Jiawei Yin | Zendy; Xiaoli Xie | Zendy; Yufu Ye | Zendy; Lijuan Wang | Zendy; Fengyuan Che | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases

Author(s) -

Jiawei Yin,

Xiaoli Xie,

Yufu Ye,

Lijuan Wang,

Fengyuan Che

Publication year - 2019

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20190604

Subject(s) - biomarker , computational biology , diagnostic biomarker , medicine , biology , genetics

Transcription factor B-cell lymphoma/leukemia 11A (BCL11A) gene encodes a zinc-finger protein that is predominantly expressed in brain and hematopoietic tissue. BCL11A functions mainly as a transcriptional repressor that is crucial in brain, hematopoietic system development, as well as fetal-to-adult hemoglobin switching. The expression of this gene is regulated by microRNAs, transcription factors and genetic variations. A number of studies have recently shown that BCL11A is involved in β-hemoglobinopathies, hematological malignancies, malignant solid tumors, 2p15-p16.1 microdeletion syndrome, and Type II diabetes. It has been suggested that BCL11A may be a potential prognostic biomarker and therapeutic target for some diseases. In this review, we summarize the current research state of BCL11A, including its biochemistry, expression, regulation, function, and its possible clinical application in human diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research